SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is surging as a short-seller retracted damaging allegations, sparking strong community discussion around a potential short squeeze and a significant rebound for the stock ahead of its upcoming earnings report.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending sharply lower following the FDA's Complete Response Letter for its RGX-121 gene therapy, citing concerns with trial design and a clinical hold linked to a potential tumor in a related program. The community is fiercely debating the severe impact on the company's immediate future and the broader gene therapy sector, while some highlight the continued value of other key pipeline assets.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its recent earnings report presented mixed results and conservative guidance, leading to a sharp market sell-off. Community discussion centers on whether the stock is oversold and fundamentally undervalued given its profitability, or if broader fintech sector headwinds and management's cautious outlook justify the decline.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following a mixed earnings report where strong Q4 results were overshadowed by lower-than-expected Q1 guidance, leading to a significant stock decline. The community is sharply divided, debating whether the dip presents a buying opportunity or if concerns about declining active clients and AI's impact on the gig economy are valid.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is a hot topic following its all-stock acquisition of Valaris, as investors debate if the newly formed offshore drilling leader, poised for over $200 million in synergies, marks the start of a significant upcycle for the stock.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending sharply lower after the abrupt departures of its CFO and general counsel amid an accounting review and delayed regulatory filings, prompting community discussions ranging from severe financial irregularity concerns to perceptions of an extreme, oversold market reaction.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv ($FISV) is trending as investors eagerly await its upcoming earnings report, creating a stark community divide between bulls citing undervaluation and strong fundamentals, and bears fearing another significant drop. Many are drawing parallels to recent struggles in the fintech sector and notable declines from companies like PayPal, contributing to heightened options activity and uncertainty.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending following a significant sell-off after it issued weaker-than-expected revenue guidance, intensifying broader market concerns that AI tools could disrupt traditional software business models. The community is divided, with many calling the drop an overreaction and a buying opportunity, while others believe AI will render such platforms obsolete.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending after reporting mixed Q1 earnings with a revenue miss attributed to transient factors, while affirming strong FY26 guidance and touting a robust and growing contract backlog. Community sentiment is notably divided between short-term disappointment over stock performance and strong long-term conviction in its pivotal role within nuclear energy, defense, and space systems.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending following its Q4 earnings report and cautious Q1 revenue guidance, which, despite an EPS beat, ignited concerns about a potential "blood bath" due to an EV market slowdown and inventory. However, bullish sentiment highlights the company's strategic investments in intelligent power and sensing for AI data centers, including a new partnership with Nvidia, as key long-term growth drivers attracting dip buyers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimates for Pharming Group Increased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Pharming Group in a note issued to...

Pharming Group Q4 EPS Forecast Increased by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2025 earnings per share estimates for shares of Pharming Group in a note...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming...

<ul class="summary-bullets"><li>FDA feedback focused on dosing and testing questions, not safety or effectiveness concerns.</li><li>Joenja’s existing approval and sales in patients aged 12 and older remain unchanged.</li><li>Pharming said it plans to work with regulators and pursue a resubmission path.</li></ul>Pharming Group shares drew heightened retail chatter on Monday after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its application to expand the use of Joenja in younger pediatric patients, while signaling confidence it can address the agency’s concerns.<h2 class="st-heading-2">FDA Requests Additional Pediatric Data</h2>Dutch drug developer Pharming announced that it had received a Complete Response Letter from the FDA on its filing for the approval of Joenja in children aged 4-11 with activated phosphoinositide 3-kinase delta syndrome (APDS).APDS is a rare primary immunodeficiency disorder in which the immune system does not function properly, resulting in recurrent infections and other complications associated with immune dysfunction. Pharming’s Joenja is an oral medication indicated to treat APDS.The company said the FDA was concerned that younger children may not be receiving sufficient doses at the proposed levels and requested additional data to confirm appropriate dosing in younger patients. The agency also flagged a technical issue with a manufacturing test and requested additional information.Pharming expressed confidence that it can resolve both inquiries. The company added that it plans to meet with the FDA to discuss next steps for resubmission, including a Type A meeting.<h2 class="st-heading-2">Approval For Older Patients Unaffected</h2>The company emphasized that the Complete Response Letter does not impact Joenja’s existing FDA approval for adult and pediatric patients aged 12 years and older, which has been in place since March 2023.CEO Fabrice Chouraqui said Pharming remains focused on making Joenja available to younger children with APDS, noting that there are currently no approved targeted treatments globally for patients under the age of 12.<h2 class="st-heading-2">Trial Results Backing The Application</h2>The application was backed by data from a late-stage clinical study in children aged 4 to 11. Pharming said that over 12 weeks of treatment, children showed reduced lymph node swelling and healthier immune cell levels, signs that the drug was helping correct the immune problem caused by APDS.Safety data from up to eight months of treatment were also included in the submission. The company said all treatment-emergent adverse events were mild to moderate, no drug-related serious adverse events were reported, and all patients completed the 12-week treatment period.In October 2025, the FDA granted the application Priority Review, citing the potential for significant improvements in the treatment of a serious condition.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Pharming was ‘bullish’ amid ‘high’ message volume ahead of the company’s Virtual Investor Day on Tuesday.One user called the FDA response a “soft” CRL, noting that it focused on dosing and testing issues rather than safety, and that Joenja remains approved and generating revenue for patients aged 12 and older.<stembedurl>https://stocktwits.com/BioSpecialOne/message/643641905</stembedurl>Another user said, “will buy the dip. Hopefully it’s a large drop”<stembedurl>https://stocktwits.com/CrispDry/message/643612689</stembedurl><a href="https://stocktwits.com/symbol/PHAR">U.S.-listed shares of Pharming</a> have surged over 130% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Pharming logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking

The company expressed confidence that it can resolve the FDA’s inquiries. 

Equity

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest...

Pharming Group (OTCMKTS:PHGUF) Sets New 1-Year High - Here's What Happened

Pharming Group (OTCMKTS:PHGUF) Hits New 12-Month High - Time to Buy...

Pharming Group (NASDAQ:PHAR) Lowered to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research note on Thursday...

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell...

Pharming Group (NASDAQ:PHAR) Shares Up 4.4% - Should You Buy?

Pharming Group (NASDAQ:PHAR) Trading 4.4% Higher - Here's What Happened...

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Should You Buy?

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Pharming Group N.V. - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.01	--	--	N/A
Q3 '25	$0.00	$0.10	2122.22%	BEAT
Q2 '25	-$0.10	$0.06	157.14%	BEAT
Q1 '25	-$0.03	-$0.22	-780.00%	MISSED
Q4 '24	$0.02	$0.05	163.16%	BEAT

PHAR
Pharming Group

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PHAR News

PHARPharming Group